Hansoh Pharmaceutical Group Company Limited
3692
Pozycja w akcjach
#905
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Cena akcji
$4.40
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$26.66B
Zmiana (1 dzień)
8.32%
Zmiana (1 rok)
-4.79%
Kraj
CN
Handel Hansoh Pharmaceutical Group Company Limited (3692)
Kategoria
Healthcare
Zyski dla Hansoh Pharmaceutical Group Company Limited (3692)
Zyski w Jun 2026 TTM: $1.14B
Według najnowszych raportów finansowych Hansoh Pharmaceutical Group Company Limited, obecny zysk firmy wynosi $1.14B. W roku 2023 firma osiągnęła zysk w wysokości $532.05M, wzrost w porównaniu do zysku z roku 2022, który wynosił $427.44M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Hansoh Pharmaceutical Group Company Limited od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $1.14B | 63.74% |
| 2024 | $696.69M | 30.94% |
| 2023 | $532.05M | 24.47% |
| 2022 | $427.44M | -17.68% |
| 2021 | $519.22M | 9.48% |
| 2020 | $474.28M | 10.05% |
| 2019 | $430.96M | 28.37% |
| 2018 | $335.73M | 13.01% |
| 2017 | $297.07M | 14.31% |
| 2016 | $259.87M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 54.69% |
IN
|
